• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Sy Mukherjee

Sy Mukherjee is a former health care reporter for Fortune.

Pentagon DNA Test Kits Warning
HealthPentagon Latest to Warn About Concerns Around DNA Test Kits
By Sy MukherjeeDecember 26, 2019
Sarepta Stock Roche Deal
HealthControversial Biotech Sarepta Keeps Up Unlikely Win Streak With $1.15 Billion Roche Deal
By Sy MukherjeeDecember 23, 2019
Brainstorm Health 2020 Signoff
NewslettersA Holiday Reflection and Temporary Farewell
By Sy MukherjeeDecember 20, 2019
Healthcare Ideas 2020s
NewslettersThe Ideas That Will Shape Health Care in the Next Decade
By Sy MukherjeeDecember 19, 2019
Big Pharma ROI
NewslettersBig Pharma’s Return on Investment Plummets to a Dismal 10-Year Low
By Sy MukherjeeDecember 18, 2019
Multiple myeloma MMRF
NewslettersGlaxoSmithKline Hopes to Take on Rivals With Rare Blood Cancer Drug
By Sy MukherjeeDecember 17, 2019
Drugs and Tech Revolutionizinf Healthcare
HealthThe 4 Most Game-Changing Medical Advances of the Past Decade
By Sy MukherjeeDecember 17, 2019
Vaping E-Cig Lung Respiratory Illness Study
NewslettersA New Study Shows the Damage Just 3 Years of Vaping Could Do to Your Lungs
By Sy MukherjeeDecember 16, 2019
Duchenne Sarepta FDA
NewslettersFDA Approves Sarepta Duchenne Drug in Stunning Reversal
By Sy MukherjeeDecember 13, 2019
Stephen Hahn FDA Commissioner Confirmed
NewslettersMeet Stephen Hahn, the New FDA Commissioner
By Sy MukherjeeDecember 12, 2019
Fertility Business MPW Next Gen
ConferencesThe 3 Things That Have Been Holding Back the Fertility Business
By Sy MukherjeeDecember 12, 2019
Home Depot Theft Opioid Crisis
NewslettersIs Loneliness Driving the Opioid Epidemic?
By Sy MukherjeeDecember 11, 2019
Flu Season 2020
NewslettersFlu Season Came Early. Here’s What You Should Do
By Sy MukherjeeDecember 9, 2019
CVS CEO Larry Merlo Aetna Deal Interview
NewslettersCVS CEO on What’s Happened After Its Aetna Merger—and What Comes Next
By Sy MukherjeeDecember 6, 2019
Biogen Alzheimers Drug Data
NewslettersThe Broader Implications of Biogen’s Divisive Alzheimer’s Drug
By Sy MukherjeeDecember 5, 2019
1...
  • 22
  • 23
  • 24
  • 25
  • 26
...100
Most Popular
Success
CEO of $20 billion AI firm Perplexity says the secret to success is ‘sleeping with that fear’ that your competitor will steal your ideaplaceholder alt text
By Preston ForeJune 13, 2026
Personal Finance
Social Security's 2032 deadline puts a 22% cut on the table — but Washington has way less room to negotiate than 1983placeholder alt text
By John W. Diamond and The ConversationJune 12, 2026
Personal Finance
Current price of oil as of June 15, 2026placeholder alt text
By Joseph HostetlerJune 15, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.